SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-013179
Filing Date
2020-11-06
Accepted
2020-11-06 16:45:43
Documents
44
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q apre-20200930x10q.htm 10-Q 1338321
2 EX-3.1 apre-20200930ex31ca25522.htm EX-3.1 135968
3 EX-31.1 apre-20200930ex311ec93f9.htm EX-31.1 9748
4 EX-31.2 apre-20200930ex312ea6987.htm EX-31.2 9739
5 EX-32.1 apre-20200930ex32182b63e.htm EX-32.1 6735
6 EX-32.2 apre-20200930ex3221bae31.htm EX-32.2 6728
  Complete submission text file 0001558370-20-013179.txt   3284255

Data Files

Seq Description Document Type Size
7 EX-101.INS apre-20200930.xml EX-101.INS 397996
8 EX-101.SCH apre-20200930.xsd EX-101.SCH 21527
9 EX-101.CAL apre-20200930_cal.xml EX-101.CAL 31028
10 EX-101.DEF apre-20200930_def.xml EX-101.DEF 55025
11 EX-101.LAB apre-20200930_lab.xml EX-101.LAB 203524
12 EX-101.PRE apre-20200930_pre.xml EX-101.PRE 139470
Mailing Address 535 BOYLSTON STREET BOSTON MA 02116
Business Address 535 BOYLSTON STREET BOSTON MA 02116 6095104718
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39069 | Film No.: 201295044
SIC: 2834 Pharmaceutical Preparations